First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1 -receptor partial agonist for the treatment of dementias.
Charlotte BakkerTim TaskerJan LiptrotEllen P HartErica S KlaassenSamantha PrinsThalia F van der DoefGiles A BrownAlastair BrownMiles CongreveMalcolm WeirFiona H MarshallDavid M CrossGeert Jan GroeneveldPradeep J NathanPublished in: British journal of clinical pharmacology (2021)
HTL0018318 showed well-characterized pharmacokinetics and following single doses were generally well tolerated in the dose range studied. These provide encouraging data in support of the development for HTL0018318 for Alzheimer's disease and other dementias.